99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors

Inclusion Criteria:

• Voluntary subjects, patients or their legal representatives sign informed consent;

• Volunteers are of any gender and aged between 18 and 75 years old, including thecut-off value;

• Other imaging methods found tumor occupying;

• Patients with pre-treatment tumors for whom surgery or biopsy may be performed toobtain final pathological results.

• Kidney glomerular filtration rate(GFR)>50 ml/min, effective renal plasmaflow(ERPF)>280 ml/min, platelet count (PLT) >75 000/μL, white blood cell (WBC) >3000/μL, alanine aminotransferase ALT, aspartate aminotransferase AST less than 3times the normal value.

Exclusion Criteria:

• People who have a history of allergy to similar drugs , allergic constitution or arecurrently suffering from allergic diseases;

• Is conducting clinical research on other drugs, or has participated in clinicalresearch on any drugs (excluding vitamins and minerals);

• Have other clinical problems that are difficult to control (such as hepatitis Cvirus infection or active hepatitis B, or other serious chronic infections andserious mental, neurological, cardiovascular, respiratory and other diseases);

• Obvious abnormal liver and kidney function, GFR less than 50 ml/min;

• Tumor load is greater than 50%, or there is obvious spinal cord compression;

• The expected survival period is less than half a year; Chemotherapy was performedwithin 6 months.

• Have severe acute concomitant diseases or serious refractory mental disorders;

• Pregnant and lactating women (where pregnancy is defined as a positive urinepregnancy study);

• Patients whose physical condition is not suitable for radiological examination;

• Other situations deemed inappropriate by the investigator to participate in thetrial.